Navigation Links
Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease
Date:10/15/2007

ing. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, including the outcome of clinical trials of Memory Pharmaceuticals' drug candidates and whether they demonstrate these candidates' safety and effectiveness; the risks and uncertainties associated with: obtaining additional financing to support Memory Pharmaceuticals' R&D and clinical activities and operations; obtaining regulatory approvals to conduct clinical trials and to commercialize Memory Pharmaceuticals' drug candidates; Memory Pharmaceuticals' ability to enter into and maintain collaborations with third parties for its drug development programs; Memory Pharmaceuticals' dependence on its collaborations and its license relationships; achieving milestones under Memory Pharmaceuticals' collaborations; Memory Pharmaceuticals' dependence on preclinical and clinical investigators, preclinical and clinical research organizations, manufacturers and consultants; and protecting the intellectual property developed by or licensed to Memory Pharmaceuticals. These and other risks are described in greater detail in Memory Pharmaceuticals' filings with the Securities and Exchange Commission. Memory Pharmaceuticals may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Memory Pharmaceuticals disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.


'/>"/>
SOURCE Memory Pharmaceuticals Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Study Suggests no Significant Impairment in Middle-of-the-Night Balance, Mobility or Memory in Older Adults Using Ramelteon
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , September 2, 2014 ... including patients, quality of life and treatment satisfaction [ ... 2 ]   ... Congress 2014, 02 September 2014, Barcelona, Spain ... of the PREvention oF thromboembolic events-European Registry in Atrial ...
(Date:9/2/2014)... YORK , September 2, 2014 ... WellPoint Inc. (NYSE: WLP ), Tekmira Pharmaceuticals ... ZTS ), Sanofi SA (NYSE: ... members receive these notes ahead of publication. To reserve ... . , ,-- ,WellPoint Inc. Research Reports ,WellPoint Inc. ...
(Date:9/2/2014)... HOUSTON , Sept. 2, 2014  Cyberonics, ... results from the ANTHEM-HF clinical study.  Results of ... specialist during a major European cardiology congress and ... Failure show Autonomic Regulation Therapy (ART) in ... and impaired heart function is safe, improves the ...
Breaking Medicine Technology:One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 2One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 3One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 4One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 5One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 6One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 7One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 8Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 2Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 3Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 4Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 5Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 6ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 2ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 3ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 4ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 5
... 20 Thomson Reuters, a global provider ... the newest version of its award-winning Clinical ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090507/NY12658LOGO) (Logo: ... hospital-based clinicians to access complete patient clinical ...
... VPHM ) third quarter financial results for 2010 ... before the open of the U.S. financial markets. ... webcast at 9:00 a.m. Eastern Time on the same day. ... third quarter financial results and other business. ...
Cached Medicine Technology:Thomson Reuters Releases iPhone Support for Clinical Xpert Navigator 2Thomson Reuters Releases iPhone Support for Clinical Xpert Navigator 3ViroPharma to Release 2010 Third Quarter Financial Results on October 27, 2010 2
(Date:9/2/2014)... September 02, 2014 On August 30, ... website titled “Why You Should Wash Your Face ... of the global population breathes air considered polluted by ... pollution lodge in the skin’s pores destroying its natural ... to free radicals that may cause cell damage, redness, ...
(Date:9/2/2014)... lay the groundwork for their own spread throughout the ... out tumor-welcoming signals, according to a new report by ... issue of Nature Communications , the researchers describe ... so-called signaling molecules released by breast cancer cells. These ... and lymph nodes to produce proteins called CCL5 and ...
(Date:9/2/2014)... Doheny HealthDay Reporter TUESDAY, ... is a driving force behind the rising rates of type ... at data from five national surveys spanning from 1976 through ... time could be explained by factors such as changing distribution ... investigators found that the prevalence of diabetes in men rose ...
(Date:9/2/2014)... (HealthDay News) -- A leading group of oncologists has ... form of advanced breast cancer. HER2-negative breast ... target the HER2 protein, the American Society of Clinical ... Almost 80 percent of women with advanced breast ... releasing this guideline, our aim is to improve both ...
(Date:9/2/2014)... ALEXANDRIA, VAThe latest research on sleep apnea, tonsillectomies, ... otolaryngic topics will be presented in Orlando, FL, ... OTO EXPO℠ of the American Academy of OtolaryngologyHead ... meeting of ear, nose, throat, head and neck ... research to be presented were released today, and ...
Breaking Medicine News(10 mins):Health News:Simon Ourian, Kim Kardashian’s Doctor: Air Pollution May Be Aging Your Skin 2Health News:‘Prepped’ by tumor cells, lymphatic cells encourage breast cancer cells to spread 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 3Health News:New Guidelines for Treating Form of Advanced Breast Cancer 2
... and the University of Florida Proton Therapy Institute have formed ... The announcement follows the approval of the first clinical study ... cancers in children younger than 3 years old. ... to receive proton therapy at the UF Proton Therapy Institute ...
... respiratory disease, often leading to disability or an increased ... Studies led by Deborah Young-Corbett, a faculty member ... specific types of sanding tools are highly effective in ... the industry,s usage of the available technology remains very ...
... -- The lives of almost 4 million women, newborns, ... year if well-established, affordable health care interventions reached 90 ... the national science academies of seven African countries. ... save lives, says the report, which calls on scientists, ...
... ... Texas , is sponsoring a new video contest inviting participants to describe why they are ... worth up to $15,000, and submitted videos will be shown on Austin Dental Spa’s website ... ...
... ... Self-service Kiosks and Pricing Transparency Patient Estimations. , ... Denver, CO (PRWEB) November 9, 2009 ... a partnership that provides patients more control when interacting with providers by understanding ...
... ... Ask4UFE to launch a podcast series that helps women suffering in silence understand their ... ... but they are life altering, says supermodel Beverly Johnson, during a new 3-part ...
Cached Medicine News:Health News:St. Jude and UF Proton Therapy Institute to begin proton therapy clinical trial 2Health News:Dust control research leads to a NIOSH grant to facilitate adoption of hazard controls 2Health News:Dust control research leads to a NIOSH grant to facilitate adoption of hazard controls 3Health News:Using science to save lives of mothers and children in Africa 2Health News:Using science to save lives of mothers and children in Africa 3Health News:Using science to save lives of mothers and children in Africa 4Health News:Austin Cosmetic Dentist Offers $15,000 Worth of Dental Work in Most Interesting Patient in the World Video Contest 2Health News:Austin Cosmetic Dentist Offers $15,000 Worth of Dental Work in Most Interesting Patient in the World Video Contest 3Health News:FHS Corp. Announces Partnership with Vecna Technologies 2Health News:New Series of Podcasts Highlight Supermodel's "Life-altering" Experience to Raise Awareness of Fibroid Treatment Options 2
... These dual pressure sensor catheters ... injection, slow-speed injection/guide wire, or ... SPC-784A for high-speed injection has ... openings and an open-end pigtail ...
... pressure intravascular catheters provide a simple, ... measuring pressures in the heart or ... catheters are ideal for high fidelity ... size from 2 to 7 French ...
... Intravascular Mikro-Tip Pressure Catheters; Millar manufactures ... pressure sensor catheters for simultaneous high ... suitable for measuring pressure gradients across ... a vascular stenosis. The catheters are ...
... pressure intravascular catheters provide a simple, ... measuring pressures in the heart or ... catheters are ideal for high fidelity ... size from 2 to 7 French ...
Medicine Products: